Less frequent zoledronic acid after first year
ASCO 2014: Less frequent zoledronic acid is safe, and has comparable efficacy for women with breast cancer and bone metastases, compared to the standard monthly treatment 30 May 2014 New findings from a phase III randomised study, OPTIMIZE-2, suggest that after a year of monthly treatment with zoledronic acid, women with breast cancer and bone […]
More